Biochemical and Biophysical Research Communications 426 (2012) 369–373

Contents lists available at SciVerse ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

ANG-(1–7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle

Mujalin Prasannarong [a,b], Fernando R. Santos [a], Erik J. Henriksen [a,*]

[a] Muscle Metabolism Laboratory, Department of Physiology, University of Arizona College of Medicine, Tucson, AZ 85721-0093, USA
[b] Exercise Physiology Laboratory, Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

ARTICLE INFO

Article history:
Received 22 August 2012
Available online 28 August 2012

Keywords:
Soleus muscle
Glucose transport
Insulin signaling
A779 peptide

ABSTRACT

The nonapeptide angiotensin II (ANG II) induces vasoconstriction via the ANG II type I receptor, while its splice product ANG-(1–7) elicits an antihypertensive effect via the Mas receptor. Although a critical role of ANG II in the etiology of skeletal muscle insulin resistance is well documented, the role of the ANG-(1–7)/Mas receptor axis in this context is poorly understood. Therefore, we determined whether ANG-(1–7) is effective in ameliorating the negative effects of ANG II on insulin-stimulated insulin signaling and glucose transport activity in isolated soleus muscle from normotensive lean Zucker rats. ANG II alone (500 nM for 2 h) decreased insulin-stimulated glucose transport activity by 45% ($P < 0.05$). In the presence of 500–1000 nM ANG-(1–7), insulin-stimulated glucose transport activity in muscle exposed to ANG II improved by ~30% ($P < 0.05$). Moreover, ANG-(1–7) treatment increased Akt Ser^{473} phosphorylation (47%, $P < 0.05$) without an effect on glycogen synthase kinase-3β Ser^{9} phosphorylation. The dependence of ANG-(1–7) action on the Mas receptor was assessed using A779 peptide, a selective Mas receptor antagonist. The positive effects of ANG-(1–7) on insulin-stimulated glucose transport activity and Akt Ser^{473} phosphorylation in soleus muscle were completely prevented in presence of 1000 nM A779. In conclusion, the present study demonstrates that ANG-(1–7), via a Mas receptor-dependent mechanism, can ameliorate the inhibitory effect of ANG II on glucose transport activity in mammalian skeletal muscle, associated with enhanced Akt phosphorylation. These results provide further evidence supporting the targeting of the renin–angiotensin system for interventions designed to reduce insulin resistance in skeletal muscle tissue.

1. Introduction

The metabolic syndrome is a clustering of cardio-metabolic abnormalities that includes obesity, impaired glucose tolerance, insulin resistance, hypertension, and dyslipidemia [1–3] and is major public-health issue in the United States and worldwide [2,4] due to the elevated risk of developing cardiovascular disease and type 2 diabetes mellitus [2,5,6]. Although there are numerous studies addressing the molecular mechanisms that link these various cardio-metabolic defects, the molecular underpinnings for the connection between insulin resistance and hypertension in particular remain poorly understood.

The renin–angiotensin system (RAS) plays numerous important roles in the regulation of the cardiovascular system. The precursor molecule angiotensinogen can be converted to angiotensin I, angiotensin II (ANG II), and angiotensin-(1–7) (ANG-(1–7)) by the peptidases renin, angiotensin converting enzyme (ACE), and ACE2, respectively [7,8]. ANG II acts through the ANG II type 1 receptor to induce its cellular actions, whereas ANG-(1–7) is a ligand for the Mas receptor [7,8]. It has been reported that alterations of ANG II and ANG-(1–7) bring about opposing effects on the cardiovascular system, in which ANG II induces a hypertensive action (vasoconstriction), while ANG-(1–7) elicits an antihypertensive effect (vasodilatation) [7,9].

The opposing metabolic actions of ANG II and ANG-(1–7) have also been addressed in a limited number of investigations. The chronic infusion of ANG II into normotensive rats induces significant reductions of whole-body insulin sensitivity, insulin-stimulated glucose transport activity in isolated soleus muscles and adipocytes, and insulin-stimulated GLUT-4 translocation to the plasma membrane [10]. Moreover, the acute *in vivo* administration of ANG II in normotensive rats causes significantly decreased engagement of critical insulin signaling proteins, including reduced phosphorylation of Akt Ser^{473}, Akt Thr^{307}, and glycogen synthase kinase-3β (GSK-3β) Ser^{9} in skeletal muscle, liver, and adipose tissue [11]. Our research group has recently demonstrated a direct negative effect of ANG II in isolated skeletal muscle to impair

* Corresponding author. Address: Muscle Metabolism Laboratory, Department of Physiology, University of Arizona College of Medicine, P.O. Box 210093, Tucson, AZ 85721-0093, USA. Fax: +1 520 621 8170.
E-mail address: ejhenrik@u.arizona.edu (E.J. Henriksen).

0006-291X/$ - see front matter © 2012 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bbrc.2012.08.093

insulin-stimulated glucose transport activity and phosphorylation of Akt Ser^{473} and GSK-3β Ser^{9} [12].

In contrast to ANG II, the chronic infusion of ANG-(1–7) into fructose-induced insulin-resistant rats causes improved whole-body insulin sensitivity [13]. In addition, the acute administration of ANG-(1–7) increases activation of Akt and GSK-3β, and the effects of ANG-(1–7) are inhibited by selective antagonism of the Mas receptor [11]. In contrast, in the Mas receptor knockout mice, insulin resistance is found at the whole-body level and in adipose tissue, accompanied by a reduction of GLUT-4 protein expression [7]. However, the direct effects of ANG-(1–7) on insulin signaling and the glucose transport system in mammalian skeletal muscle under highly defined *in vitro* conditions have yet to be investigated.

Although a critical role of ANG II in the etiology of mammalian skeletal muscle insulin resistance is well documented [14], the importance of the ANG-(1–7)/Mas receptor axis in this context is less well understood. Therefore, the objectives of this study were (1) to determine whether ANG-(1–7) is effective in ameliorating the negative effects of ANG II on insulin-stimulated insulin signaling and glucose transport activity in isolated soleus muscle from lean Zucker rats, and (2) to assess whether these actions of ANG-(1–7) are dependent on the Mas receptor by using the selective Mas receptor antagonist A779 [15].

2. Methods

2.1. Animals

All procedures were approved by the University of Arizona Animal Use and Care Committee. Female lean Zucker rats (HsdHlr:ZUCKER-*Lepr+*; Harlan, Indianapolis, IN) weighing 130–150 g were used at 6–8 weeks of age. All animals were housed in a temperature-controlled room (20–22 °C) with a 12:12 h light/dark cycle (lights on from 7 AM to 7 PM) at the College of Medicine Animal Care Facility of the University of Arizona. The animals had free access to chow (Purina, St. Louis, MO) and water. Animals were restricted to 4 g of chow starting at 5 PM on the evening before each experiment. Experiments began between 8 and 9 AM the next day.

2.2. Assessment of glucose transport activity

Animals were deeply anesthetized with pentobarbital sodium (50 mg/kg ip) (Akorn, Inc., Decatur, IL). Soleus muscles were dissected and prepared for *in vitro* incubation [16]. These isolated muscle strips were used for determining 2-deoxyglucose uptake as described previously [17]. Briefly, muscle strips (~25–35 mg) were initially incubated for 2 h at 37 °C in 3 ml of oxygenated (95% O_2/5% CO_2) Krebs–Henseleit buffer (KHB) containing 8 mM glucose, 32 mM mannitol, and 0.1% bovine serum albumin (Sigma Chemical, St. Louis, MO) in the absence or presence of 5 mU/ml insulin (Humulin R, Eli Lilly, Indianapolis, IN), 500 nM ANG II (Sigma Chemical, St. Louis, MO), 500–1000 nM ANG (1–7) (Sigma Chemical, St. Louis, MO), and/or 1000 nM A779 (GenWay Biotech, San Diego, CA). After this initial incubation, the muscles were rinsed for 10 min at 37 °C in 3 ml of oxygenated KHB rinse containing 40 mM mannitol and 0.1% BSA in the absence or presence of any previous additions. Afterward, the muscles were transferred to 2 ml oxygenated KHB containing 1 mM 2-deoxy[1,2-3H]glucose (300 mCi/mmol; Sigma Chemical, St. Louis, MO), 39 mM [U-14C]mannitol (0.8 mCi/mmol; ICN Radiochemicals, Irvine, CA), 0.1% BSA, and/or insulin, ANG II, ANG (1–7), and A779, if present previously, for 20 min. After the final incubation, muscles were removed, trimmed of fat and connective tissue, quickly frozen in liquid nitrogen, and weighed. The frozen muscles were then dissolved in 0.5 ml of 0.5 N NaOH at 60 °C, and 5 ml of scintillation cocktail (MP Biomedicals, Solon, OH) were added. The intracellular accumulation of the glucose analog 2-DG was measured as described previously [17,18].

2.3. Determination of insulin signaling

Soleus muscle strips were incubated for 2 h at 37 °C in 3 ml of oxygenated KHB containing 8 mM glucose, 32 mM mannitol, 0.1% bovine serum albumin, and 500 nM ANG II in the absence or presence of 5 mU/ml insulin, 1000 nM ANG-(1–7), and/or 1000 nM A779. After the incubation, muscles were removed, trimmed of fat and connective tissue, and quickly frozen in liquid nitrogen, weighed, and stored at −80 °C. The frozen soleus muscles were homogenized in eight volumes of ice-cold lysis buffer (50 mM Hepes, 150 mM NaCl, 20 mM Na pyrophosphate, 20 mM β-glycerophosphate, 10 mM NaF, 2 mM Na_3VO_4, 2 mM EDTA, 1% Triton X-100, 10% glycerol, 1 mM $MgCl_2$, 1 mM $CaCl_2$, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 0.5 μg/ml pepstatin, and 2 mM PMSF). After 20-min incubation on ice, homogenates were centrifuged at 13,000*g* for 20 min at 4 °C. Total protein assay was used to determine by the BCA method (Pierce Biotechnology, Rockford, IL). Proteins were separated by SDS–PAGE on 10% polyacrylamide gels and transferred to nitrocellulose membranes. Protein blots of samples were incubated overnight with antibodies against Akt1/2, phospho-Akt Ser^{473}, phospho-glycogen synthase kinase-3α/β (GSK-3α/β) $Ser^{21/9}$ (Cell Signaling Technology, Danvers, MA), and GSK-3 (Millipore, Billerica, MA). Thereafter, the membranes were incubated with secondary goat anti-rabbit antibody conjugated with horseradish peroxidase (HRP) (Chemicon, Temecula, CA) or anti-mouse antibody conjugated with HRP (Santa Cruz Biotechnology, Santa Cruz, CA). Proteins were visualized using a Bio-Rad Chemidoc XRS instrument (Bio-Rad Laboratories, Hercules, CA) using the SuperSignal West Femto Maximum Sensitivity Western blot detection substrate (Pierce Biotechnology, Rockford, IL). Band density was quantified using the Bio-Rad Quantity One software.

2.4. Statistical analysis

Data are expressed as means ± SE. Differences between the treatment groups versus the basal groups for glucose transport activity were determined by one-way analysis of variance (ANOVA) followed by a Dunnett's test. Paired Student's *t*-tests were employed to determine statistically significant differences between groups treated without or with either ANG-(1–7) or A779. A value of $P < 0.05$ was considered to be statistically significant.

3. Results

3.1. Effects of ANG-(1–7) on glucose transport activity in ANG II-treated skeletal muscle

To determine whether ANG-(1–7) directly modulates glucose transport activity in mammalian skeletal muscle, we measured the effects of 500 and 1000 nM ANG (1–7) on basal and insulin-stimulated glucose transport activities of isolated soleus muscle treated with 500 nM ANG II (Fig. 1). Neither ANG II nor ANG-(1–7) at either concentration had any effect on the basal glucose transport activity (Fig. 1A). As shown in Fig. 1B, the rate of insulin-stimulated glucose transport was decreased by 45% ($P < 0.05$) in the presence of ANG II. The addition of 500 or 1000 nM ANG (1–7) attenuated this inhibitory effect of ANG II on insulin-stimulated glucose transport activity by ~30% ($P < 0.05$). These results indicate a positive effect of ANG-(1–7) to ameliorate ANG II-induced insulin



Fig. 1. Glucose transport activity in isolated skeletal muscle under basal (A) or insulin-stimulated (B) conditions in the absence or presence of ANG II and ANG-(1–7). Values are means ± SE for 4–8 muscles/group. *$P < 0.05$ vs. + insulin + ANG II.

resistance of glucose transport activity in mammalian skeletal muscle.

3.2. Effects of ANG-(1–7) on insulin signaling in ANG II-treated skeletal muscle

Phosphorylation of Akt Ser^{473} and GSK-3β Ser^{9} were evaluated to address the molecular mechanisms involved in the improvement of glucose transport activity by ANG-(1–7) in ANG II-induced insulin resistance (Fig. 2). In the absence of insulin, ANG-(1–7) had no effect on Akt Ser^{473} phosphorylation (Fig. 2A). ANG-(1–7) significantly increased (47%, $P < 0.05$) insulin stimulation of Akt Ser^{473} phosphorylation in ANG II-induced insulin-resistant skeletal muscle (Fig. 2B). There was no effect of ANG-(1–7) on GSK-3β Ser^{9} phosphorylation in either the absence or presence of insulin (Fig. 2C and D). These results suggest that ANG-(1–7) improves insulin action via engagement of Akt Ser^{473} phosphorylation in ANG II-induced insulin-resistant skeletal muscle.

3.3. Effects of Mas receptor antagonism on ANG-(1–7)-mediated improvement of glucose transport activity and Akt phosphorylation in ANG II-treated skeletal muscle

To determine if ANG-(1–7) mediates its metabolic actions through the Mas receptor, the selective Mas receptor antagonist A779 [15] was used. Soleus muscles were exposed to insulin and



Fig. 2. Effect of ANG-(1–7) on basal and insulin-simulated Akt Ser^{473} phosphorylation (A and B) and GSK-3β Ser^{9} phosphorylation (C and D) in ANG II-treated muscles. Values are means ± SE for 7–8 muscles/group. *$P < 0.05$ vs. + insulin + ANG II − ANG-(1–7).



Fig. 3. Effect of Mas receptor antagonism on the ANG-(1–7)-mediated improvement of insulin-stimulated glucose transport activity in the presence of ANG II. Values are means ± SE for 4 muscles/group. *$P < 0.05$ vs. + insulin + ANG II − A779.



Fig. 4. Effect of Mas receptor antagonism on the ANG-(1–7)-mediated improvement of insulin-stimulated Akt Ser^{473} phosphorylation in the presence of ANG II. Values are means ± SE for 6 muscles/group. *$P < 0.05$ vs. + insulin + ANG II − A779.

ANG II without or with ANG-(1–7) and/or A779. As shown in Fig. 3, A779 itself had no effect on insulin-stimulated glucose transport activity of ANG II-induced insulin-resistant muscles. In contrast, A779 completely prevented the significant positive effect of ANG-(1–7) on ANG II-induced insulin resistance of glucose transport activity. Moreover, the increase of Akt Ser^{473} phosphorylation in the ANG (1–7)-treated group was completely inhibited ($P < 0.05$) by the Mas receptor antagonist A779 (Fig. 4). These observations indicate that the actions of ANG-(1–7) to reduce ANG II-induced insulin resistance are dependent on engagement of the Mas receptor to enhance Akt phosphorylation.

4. Discussion

In the present investigation, we have made the novel findings that (1) ANG-(1–7), which is produced primarily by the action of the peptidase ACE2 on ANG II [8], can partially (~30%) reverse the insulin resistance of glucose transport activity caused by ANG II in isolated mammalian skeletal muscle (Fig. 1B); (2) the ANG-(1–7)-induced improvement in glucose transport activity is associated with an increase in Akt Ser^{473} phosphorylation (Fig. 2B), but not GSK-3β Ser^{9} phosphorylation (Fig. 2D); and (3) these improvements in insulin action on glucose transport activity and Akt Ser^{473} phosphorylation elicited by ANG-(1–7) are dependent on engagement of the Mas receptor (Figs. 3 and 4). These findings underscore the fact that ANG II and ANG-(1–7) not only play well-recognized counterbalancing roles in the regulation of numerous cardiovascular, neurological, renal, and pulmonary functions [7–9,19], but also function to oppose each other's actions in critical metabolic processes, such as insulin signaling and insulin-dependent glucose transport activity in mammalian skeletal muscle.

ANG II induces insulin resistance in skeletal muscle tissue (reviewed in Refs. [14,20]). In cultured skeletal muscle cell lines, this action of ANG II to diminish insulin-stimulated GLUT-4 translocation to the plasma membrane is associated with reduced functionality of proximal and distal insulin signaling proteins [21,22]. Moreover, in actual mammalian skeletal muscle preparations, we have demonstrated that ANG II directly impairs insulin-stimulated glucose transport activity by a mechanism involving reduced engagement of Akt Ser^{473} phosphorylation and GSK-3β Ser^{9} phosphorylation [12]. Several studies have suggested that ANG II induces its deleterious effects on skeletal muscle insulin action via a mechanism that includes the activation of NADPH oxidase, thereby producing reactive oxygen species (ROS) which then impair function of the insulin-dependent glucose transport system [14,21,23].

In the present study, we have assessed these opposing effects of ANG II and ANG-(1–7) on the insulin-dependent glucose transport system in isolated rat skeletal muscle. We have made the novel observation in this tissue that ANG-(1–7) can partially restore insulin-stimulated glucose transport activity in skeletal muscle made insulin-resistant by exposure to ANG II (Fig. 1B), associated with a significant enhancement of insulin-stimulated Akt Ser^{473} phosphorylation (Fig. 2B). Similar effects of ANG-(1–7) have been reported in a study using rats made insulin-resistant with high-fructose diet, in which impairment of the functionality of proximal and distal insulin signaling elements are induced [13]. In these animals, the chronic infusion of ANG-(1–7) group leads to improvements in insulin-stimulated tyrosine phosphorylation of the insulin receptor and IRS-1 and in Akt Ser^{473} phosphorylation in skeletal muscle. These results from the study of Giani et al. [13] and the present results support the concept that ANG-(1–7) increases insulin-stimulated glucose transport activity in insulin-resistant skeletal muscle by a mechanism involving enhanced Akt Ser^{473} phosphorylation.

In the absence of insulin, we found no effect of ANG (1–7) on basal glucose transport activity, Akt Ser^{473}, or GSK-3β Ser^{9} phosphorylation. These results are similar to those from the study of Giani et al. [13] using high fructose-fed rats treated chronically with ANG-(1–7), in which no significant effect of ANG-(1–7) treatment on Akt Thr^{308} phosphorylation in the control group or in the high fructose-fed group was seen in the absence of an acute intravenous insulin infusion [13]. In contrast, a direct, acute intravenous injection of ANG-(1–7) into normal rats in the absence of elevated plasma insulin concentrations did increase phosphorylation of Akt Ser^{473}, Akt Thr^{308}, and GSK-3β Ser^{9} in skeletal muscle [11]. An explanation for these apparently contradictory results is not obvious, but may relate to differences in the animal model used, the route of administration of ANG-(1–7), and the effective concentration of ANG (1–7) achieved.

To test whether ANG (1–7) acts through the Mas receptor in isolated skeletal muscle, the selective Mas receptor antagonist A779 [17] was used. In the present study, antagonism of the Mas receptor using this peptide inhibitor completely prevented the beneficial effects of ANG-(1–7) to ameliorate the negative actions of ANG II on insulin-stimulated glucose transport activity (Fig. 3) and Akt Ser^{473} phosphorylation (Fig. 4). This same dependence on a functional Mas receptor for the actions of ANG-(1–7) on insulin signaling was observed in normal, insulin-sensitive rats treated acutely with ANG-(1–7) [11]. Interestingly, we have observed that the protein expression of the Mas receptor is not different in skeletal muscle, abdominal adipose tissue, liver, or myocardium from lean and obese Zucker rats (Prasannarong and Henriksen, unpublished data). Taken together, these results support the concept that ANG-(1–7) activates insulin signaling (including Akt phosphorylation) and stimulates glucose transport activity in isolated skeletal muscle through a Mas receptor-depend mechanism.

In summary, this study is the first study to report the direct positive effects of ANG-(1–7) on insulin-dependent glucose metabolism in ANG II-induced insulin-resistant isolated mammalian skeletal muscle. Our results demonstrate that ANG-(1–7), via a Mas receptor-dependent mechanism, can ameliorate the inhibitory effect of ANG II on glucose transport activity in mammalian skeletal muscle, associated with enhanced Akt phosphorylation. The present findings support the utility of interventions that engage the ACE2/ANG-(1–7)/Mas receptor axis to reduce insulin resistance of the glucose transport system in mammalian skeletal muscle caused by RAS overactivity.

Acknowledgments

This study was supported by the Guenther J. Dietze Foundation and by the Strategic Scholarships for Frontier Research Network for the Joint Ph.D. Program from the Commission on Higher Education, Thailand.

References

[1] G.M. Reaven, Role of insulin resistance in human disease (syndrome X): an expanded definition, Annu. Rev. Med. 44 (1993) 121–131.
[2] P. Zimmet, D. Magliano, Y. Matsuzawa, G. Alberti, J. Shaw, The metabolic syndrome: a global public health problem and a new definition, J. Atheroscler. Thromb. 12 (2005) 295–300.
[3] P.L. Huang, A comprehensive definition for metabolic syndrome, Dis. Models Mech. 2 (2009) 231–237.
[4] R.H. Eckel, S.M. Grundy, P.Z. Zimmet, The metabolic syndrome, Lancet 365 (2005) 1415–1428.
[5] S.M. Grundy, B. Hansen, S.C. Smith Jr., J.I. Cleeman, R.A. Kahn, Clinical management of metabolic syndrome: report of the American Heart Association/National Heart Lung and Blood Institute/American Diabetes Association conference on scientific issues related to management, Circulation 109 (2004) 551–556.
[6] R. Kahn, J. Buse, E. Ferrannini, M. Stern, The metabolic syndrome: time for a critical appraisal Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia 48 (2005) 1684–1699.
[7] R.A. Santos, A.J. Ferreira, A.C. Simões E. Silva, Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis, Exp. Physiol. 93 (2008) 519–527.
[8] P. Xu, S. Sriramula, E. Lazartigues, ACE2/ANG-(1–7)/Mas pathway in the brain the axis of good Am, J. Physiol. Regul. Integr. Comp. Physiol. 300 (2011) R804–R817.
[9] A.N. Cat, R.M. Touyz, A new look at the renin–angiotensin system – focusing on the vascular system, Peptides 32 (2011) 2141–2150.
[10] T. Ogihara, T. Asano, K. Ando, Y. Chiba, H. Sakoda, M. Anai, N. Shojima, H. Ono, Y. Onishi, M. Fujishiro, H. Katagiri, Y. Fukushima, M. Kikuchi, N. Noguchi, H. Aburatani, I. Komuro, T. Fujita, Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling, Hypertension 40 (2002) 872–879.
[11] M.C. Muñoz, J.F. Giani, F.P. Dominici, Angiotensin-(1–7) stimulates the phosphorylation of Akt in rat extracardiac tissues *in vivo* via receptor Mas, Regul. Pept. 161 (2010) 1–7.
[12] M.K. Diamond-Stanic, E.J. Henriksen, Direct inhibition by angiotensin II of insulin dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism, Arch. Physiol. Biochem. 116 (2010) 88–95.
[13] J.F. Giani, M.A. Mayer, M.C. Muñoz, E.A. Silberman, C. Höcht, C.A. Taira, M.M. Gironacci, D. Turyn, F.P. Dominici, Chronic infusion of angiotensin-(1–7) improves insulin resistance and hypertension induced by a high-fructose diet in rats Am, J. Physiol. Endocrinol. Metab. 296 (2009) E262–E271.
[14] E.J. Henriksen, M.K. Diamond-Stanic, E.M. Marchionne, Oxidative stress and the etiology of insulin resistance and type 2 diabetes, Free Radic. Biol. Med. 51 (2011) 993–999.
[15] R.A. Santos, M.J. Campagnole-Santos, N.C. Baracho, M.A. Fontes, L.C. Silva, L.A. Neves, D.R. Oliveira, S.M. Caligiorne, A.R. Rodrigues, C. Gropen Júnior, et al., Characterization of a new angiotensin antagonist selective for angiotensin-(1–7): evidence that the actions of angiotensin-(1–7) are mediated by specific angiotensin receptors, Brain Res. Bull. 35 (1994) 293–298.
[16] E.J. Henriksen, R.E. Bourey, K.J. Rodnick, L. Koranyi, M.A. Permutt, J.O. Holloszy, Glucose transporter protein content and glucose transport capacity in rat skeletal muscles, Am. J. Physiol. Endocrinol. Metab. 259 (1990) E593–E598.
[17] E.J. Henriksen, A.E. Halseth, Early alterations in soleus GLUT-4 glucose transport and glycogen in voluntary running rats, J. Appl. Physiol. 76 (1994) 1862–1867.
[18] E.J. Henriksen, S. Jacob, Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats, Metabolism 44 (1995) 267–272.
[19] A.J. Ferreira, R.A.S. Santos, C.N. Bradford, A.P. Mecca, C. Sumners, M.J. Katovich, M.K. Raizada, Therapeutic implications of the vasoprotective axis of the renin–angiotensin system in cardiovascular diseases, Hypertension 55 (2010) 207–213.
[20] E.J. Henriksen, Improvement of insulin sensitivity by antagonism of the renin–angiotensin system, Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2007) R974–R980.
[21] Y. Wei, J.R. Sowers, R. Nistala, H. Gong, G.M. Uptergrove, S.E. Clark, E.M. Morris, N. Szary, C. Manrique, C.S. Stump, Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells, J. Biol. Chem. 281 (2006) 35137–35146.
[22] A. Csibi, D. Communi, N. Müller, S.P. Bottari, Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms, PLoS One 5 (2010) e10070.
[23] K.K. Griendling, C.A. Minieri, J.D. Ollerenshaw, R.W. Alexander, Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells, Circ. Res. 74 (1994) 1141–1148.